Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$59 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.3
Industry P/E
24.51
EV/EBITDA
-1.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1
Face value
--
Shares outstanding
34,543,561
CFO
$-168.86 Mln
EBITDA
$-173.99 Mln
Net Profit
$-190.78 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ibio Inc (IBIO)
| 2.6 | -29.8 | 2.6 | -- | -- | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ibio Inc (IBIO)
|
2.0 | 59.1 | 0.3 | -24.7 | -7,518.3 | -69.3 | -- | 1.3 |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved... CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 11750 Sorrento Valley Road, San Diego, CA, United States, 92121 Read more
CEO & Chief Scientific Officer
Dr. Martin B. Brenner D.V.M., Ph.D.
Chief Financial Officer
Mr. Felipe Duran
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ibio Inc (IBIO) is $1.98 (NYSE) and $1.98 (NASDAQ) as of 02-Apr-2026 19:09 EDT. Ibio Inc (IBIO) has given a return of --% in the last 1 years.
Since, TTM earnings of Ibio Inc (IBIO) is negative, P/E ratio is not available.
The P/B ratio of Ibio Inc (IBIO) is 1.29 times as on 31-Mar-2026, a 77 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.70
|
0.86
|
|
2024
|
-0.73
|
0.85
|
|
2023
|
-0.02
|
0.04
|
|
2022
|
-0.05
|
0.04
|
|
2021
|
-0.03
|
0.01
|
The 52-week high and low of Ibio Inc (IBIO) are Rs 3.82 and Rs 1.17 as of 04-Apr-2026.
Ibio Inc (IBIO) has a market capitalisation of $ 59 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ibio Inc (IBIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.78
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.